2 days Ago
Tevogen Bio Holdings press release ( NASDAQ: TVGN ): Q3 Improved operating performance by reducing net loss by $52.5 million; reported net loss of $4.3 million and $56.
8 million for the nine months ended September 30, for 2024 and 2023, respectively. Significantly improved financial position by eliminating nearly all of its liabilities; reported $10.5 million as of September 30, 2024, and $99.
9 million as of December 31, 2023. Approximately 78% of equity retained by Tevogen officers. More on Tevogen Bio Holdings Financial information for Tevogen Bio Holdings.
